메뉴 건너뛰기




Volumn 44, Issue 11, 2004, Pages 921-923

Natural progression of Alzheimer's disease (AD): A perspective on possible therapies for advanced AD

Author keywords

Acetylcholine; Alzheimer's disease; Amyloid protein

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; GALANTAMINE;

EID: 10944271838     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper
Times cited : (3)

References (7)
  • 1
    • 0011162190 scopus 로고
    • Selective loss of central cholinergic neurons in Alzheimer's disease
    • Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403
    • (1976) Lancet , vol.2 , pp. 1403
    • Davies, P.1    Maloney, A.J.2
  • 2
    • 0020072221 scopus 로고
    • Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
    • Whitehouse PJ, Price DL, Struble RG, et al: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-1239
    • (1982) Science , vol.215 , pp. 1237-1239
    • Whitehouse, P.J.1    Price, D.L.2    Struble, R.G.3
  • 3
    • 0035103036 scopus 로고    scopus 로고
    • Open-label, multicenter, phase 3 extension study of the safety and efficacy of denepezil in patients with Alzheimer disease
    • Doody RS, Geldmacher DS, Gordon B, et al: Open-label, multicenter, phase 3 extension study of the safety and efficacy of denepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427-433
    • (2001) Arch Neurol , vol.58 , pp. 427-433
    • Doody, R.S.1    Geldmacher, D.S.2    Gordon, B.3
  • 4
    • 0035964226 scopus 로고    scopus 로고
    • A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
    • Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-620
    • (2001) Neurology , vol.57 , pp. 613-620
    • Feldman, H.1    Gauthier, S.2    Hecker, J.3
  • 5
    • 0037236816 scopus 로고    scopus 로고
    • Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months
    • Blesa R, Davidson M, Kurz A, et al: Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003; 15: 79-87
    • (2003) Dement Geriatr Cogn Disord , vol.15 , pp. 79-87
    • Blesa, R.1    Davidson, M.2    Kurz, A.3
  • 6
    • 0034737299 scopus 로고    scopus 로고
    • Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
    • Yamamoto A, Lucas JJ, Hen R: Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101: 57-66
    • (2000) Cell , vol.101 , pp. 57-66
    • Yamamoto, A.1    Lucas, J.J.2    Hen, R.3
  • 7
    • 0033536163 scopus 로고    scopus 로고
    • Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
    • Schenk D, Barbour R, Dunn W, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177
    • (1999) Nature , vol.400 , pp. 173-177
    • Schenk, D.1    Barbour, R.2    Dunn, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.